Paris (ots/PRNewswire) - - Human and in vivo Studies Indicate Lantus(R) Metabolites do not ConferCarcinogenic Potential via IGF-1 Receptor Activation Sanofi announced at the 71st American Diabetes Association Scientific Sessions 2011 the results of four studies[1,2,3,4] indicating that the effect of Lantus(R) (insulin glargine) metabolites on the IGF-1 receptor is ...
Astellas Pharma Europe Limited
London (ots/PRNewswire) - Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor. The study is evaluating AC220 as an oral, once-a-day, monotherapy treatment in acute myeloid ...
Bristol-Myers Squibb GmbH & Co. KGaA
Paris (ots/PRNewswire) - Five-year follow-up results were presented today from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia(CP-CML) adult patients resistant or intolerant to imatinib mesylate. At ...
Copenhagen, Denmark (ots/PRNewswire) - - NOT INTENDED FOR US MEDIA - Ingenol Mebutate is an Investigational Two-to-Three Day Topical Treatment for Precancerous Skin Disease Clinical data from four Phase 3 studies of ingenol mebutate gel, an investigational treatment for actinic keratosis, were presented publicly for ...
Bristol-Myers Squibb GmbH & Co. KGaA
Princeton, New Jersey (ots/PRNewswire) - - Study 024 Evaluated Newly-Diagnosed Patients Treated with YERVOY at Investigational Dose of 10mg/kg in Combination with Dacarbazine vs. Dacarbazine Alone - Forty-Seven Percent of Patients Treated with YERVOY Plus Dacarbazine Alive at One Year, 28 Percent Alive at Two Years ...
company: AGENNIX AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 89 8565 2693 FAX: +49 89 8565 2610 mail: ir@agennix.com WWW: http://www.agennix.com sector: Pharmaceuticals ISIN: DE000A1A6XX4 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: regulated dealing/prime standard: Frankfurt, ...
company: AGENNIX AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 89 8565 2693 FAX: +49 89 8565 2610 mail: ir@agennix.com WWW: http://www.agennix.com sector: Pharmaceuticals ISIN: DE000A1A6XX4 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: regulated dealing/prime standard: Frankfurt, ...
Bristol-Myers Squibb GmbH & Co. KGaA
Paris (ots/PRNewswire) - YERVOY (ipilimumab) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with previously-treated unresectable or metastatic melanoma. The European Commission will consider the CHMP's positive opinion in its decision on ...
Total Group revenues up 17.8 percent to EUR 307.5 million After-tax loss of EUR 2.6 million better than previous year comparative (EUR 4.4 million loss) Orders received up 24.1 percent to EUR 363.9 million (previous year: EUR 293.2 million) Orders in hand in Resources segment boosted to high level of ...
London (ots/PRNewswire) - Lonrho's Oceanfresh has announced that after a lengthy product testing and development program Oceanfresh has been chosen to supply 16 of the 19 items that Pick n Pay will be launching under their private label brand. The new range includes product lines for general day to day consumption as well as new products that will form part of the prestigious 'Finest Range' category from Pick n Pay. First ...
Total Group revenues up 2.2 percent to EUR 1,304 million Profit after tax of EUR 39.8 million (previous year: EUR 42.0 million) to plan Orders received up 26.7 percent to EUR 1,410.0 million (previous year: EUR 1,113.1 million) Forecast for 2011: Total Group revenues up to EUR 1.4 billion and profit ...
Contact: Manuel TAVERNE POLYTEC GROUP Investor Relations Tel.+43(0)7221/701-292 manuel.taverne@polytec-group.com Branche: Industrial Components ISIN: AT0000A00XX9 WKN: A0CA1R Index: ATX Prime Börsen: Wien / official market ...
Contact: Gerick Thomas Branche: Software ISIN: DE000A0BVU28 WKN: A0BVU2 Index: CDAX, Prime All Share, Technology All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Hamburg / free trade Düsseldorf / free trade Hannover / free trade München / free trade Stuttgart / regulated dealing ...
Astellas Pharma Europe Limited
Tokyo (ots/PRNewswire) - Astellas Pharma Inc. (http://www.astellas.com/en/corporate/) today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition.(1,2) These data were presented for the ...
Bristol-Myers Squibb GmbH & Co. KGaA
Paris (ots/PRNewswire) - Bristol-Myers Squibb announced today that BARACLUDE(R) (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease. BARACLUDE(r) was already approved in Europe in June 2006 ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Research & Development Vancouver, BC VJ 2M9 (euro adhoc) - Opawica Explorations Inc. (TSX.V: OPW) ("Opawica"/ the "Company") announces the following drill hole results from the Company's 100% owned Atikwa Lake gold and copper project, ...
Barcelona, Spain (ots/PRNewswire) - As the first European operator to announce that we would deploy a new generation of SIM cards and handsets to facilitate mobile contactless services, Orange has extended its successful and long-term relationship with Samsung to deliver handsets enabled for NFC (Near ...
Softline establishes its Belgian subsidiary Softline Solutions N.V. - in Zaventem near Brussels Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Global Expansion/Plant Openings Subtitle: Softline establishes its Belgian subsidiary Softline Solutions N.V. - in Zaventem near ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Research & Development Vancouver, Canada (euro adhoc) - Opawica Explorations Inc. (TSX.V: OPW / OTC: OPWEF / Frankfurt: 0E5A) ("Opawica"/ the "Company") announces the following drill ...
Bristol-Myers Squibb GmbH & Co. KGaA
Paris (ots/PRNewswire) - Bristol-Myers Squibb today announced that SPRYCEL(R) (dasatinib) 100mg once daily received Marketing Authorization from the European Commission for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukaemia in Chronic Phase ...
Chicago, November 16 (ots/PRNewswire) - New results from an observational substudy from TRITON-TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient(R)/Effient(R) (prasugrel) prior to coronary artery bypass graft surgery (CABG) ...
Total Group revenues up 1.9 percent from EUR 944.5 million to EUR 962.6 million Sales revenues up 8.0 percent to EUR 844.4 million (previous year: EUR 782.2 million) Profit after tax EUR 21.0 million (previous year: EUR 30.0 million) Orders received up 27.7 percent to EUR 1,042.1 million (previous ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information VANCOUVER, Canada (euro adhoc) - Opawica Explorations Inc. (TSX.V: OPW / OTC: OPWEF / Frankfurt: OE5A) ("Opawica" / the "Company") announces the following drill hole results from the Company's Atikwa Lake gold and copper project near Kenora, Ontario. Results ...
Bristol-Myers Squibb GmbH & Co. KGaA
Paris (ots/PRNewswire) - Bristol-Myers Squibb today announced that SPRYCEL(r) (dasatinib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive Chronic Myelogenous Leukaemia in Chronic ...
The International Menopause Society (IMS)
London (ots/PRNewswire) - To mark World Menopause Day on 18th October 2010, the International Menopause Society (IMS) is launching new Recommendations for the management of postmenopausal vaginal atrophy, a distressing condition that will affect up to half of women after menopause.[1] This new guidance is ...
Paris (ots/PRNewswire) - The Etam muse, designer of two lingerie collections a year and Russian top model, Natalia Vodianova, is continuing her collaboration with the French brand. Seduction, joy, generosity, fashion and pleasure are the true common values that unite Etam and Natalia Vodianova. To view the Multimedia News Release, please click: http://multivu.prnewswire.com/mnr/prne/etam/44220/ With a ...
London and San Francisco (ots/PRNewswire) - AstraZeneca's new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc. , significantly improved outcomes of patients with rheumatoid arthritis (RA) who responded inadequately to ongoing treatment with methotrexate (MTX), ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden. The first pooled analysis using patient-level data from randomized clinical trials demonstrated that adding ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the ...
Antony, France (ots/PRNewswire) - Stallergenes S.A. has announced today the signing of exclusive partnership agreements with Shionogi & Co., Ltd. for two sublingual allergen immunotherapy tablet products resulting from the Stalair(R) program: Actair(R) house dust mite tablets and Japanese cedar pollen tablets. With 32 million respiratory allergy sufferers, there ...